HK:1244 Stock Latest News
Company Announcements3D Medicines Hits Key Phase 3 Milestone for AML Vaccine Candidate3d ago1244
Company Announcements3D Medicines Updates Cayman Share Registrar, Keeps Hong Kong Arrangements Intact1M ago1244
Company Announcements3D Medicines Extends HK$50 Million Note at Higher Coupon1M ago1244
Company Announcements3D Medicines Completes Key Early Trial in Blood Cancer, Setting Up Next Phase of Growth1M ago1244
Company Announcements3D Medicines Boosts Envafolimab Sales and Deepens Oncology Pipeline in H1 20262M ago1244
Company Announcements3D Medicines Fully Enforces Arbitration Win Against SELLAS as Key Trial Nears Endpoint2M ago1244Company Announcements3D Medicines Sets Board Meeting to Approve Interim Results and Consider Dividend2M ago1244
Company Announcements3D Medicines Revamps Board as Finance Veteran Joins After Non-Executive Director Steps Down2M ago1244
- Company Announcements3D Medicines Details Board and Committee Structure2M ago1244
- Company Announcements3D Medicines Updates Hong Kong Process Agent and Moves Principal Office2M ago1244
Company Announcements3D Medicines Wins Arbitration Against SELLAS, Licence Deal Intact3M ago1244
Company Announcements3D Medicines Shareholders Approve All AGM Resolutions, Expand Capital Mandates4M ago1244
Company Announcements3D Medicines consolidates company secretary and authorised representative roles4M ago1244Company Announcements3D Medicines Sets 2026 AGM to Approve Results, Board Changes and Share Mandate4M ago1244
Company Announcements3D Medicines’ Envafolimab Trial in Biliary Tract Cancer to Headline 2026 ASCO Meeting5M ago1244
- Company Announcements3D Medicines Completes Phase III Envafolimab Lung Cancer Trial Enrollment Ahead of Schedule5M ago1244
- Company Announcements3D Medicines Extends HK$50 Million Note to Puxin, Flags Disclosure Lapse7M ago1244
Company Announcements3D Medicines Advances Oncology Platforms Despite Envafolimab Revenue Dip in 20257M ago1244- Company Announcements3D Medicines Sets March 31 Board Meeting to Approve 2025 Results and Mull Dividend7M ago1244
Company Announcements3D Medicines Moves Envafolimab Toward Full Approval in China8M ago1244Company Announcements3D Medicines’ Envafolimab NDA for First-Line Biliary Tract Cancer Accepted by China’s NMPA9M ago1244